Shared risk or competition for emerging assets: How can we optimise the Pharma-VC relationship?
Frédéric Legros (PhD) is an experienced business professional with a passion for life sciences and business. He has over a decade of experience in licensing and business development. He studied biotechnology at University of Paris 7, obtained his PhD in molecular biology (2002), and published several publications in peer-reviewed journals while at the Institute of Myology (Paris). He also holds a business degree from NEOMA Business School, France (2003). Frédéric joined Dynacure in January 2017 as Chief Operating Officer.
Before joining Dynacure, Frédéric was Vice President and Corporate Head of Business Development of Valneva SE, a listed company on the French stock exchange, where he developed and commercialized vaccines. Frédéric served on the board of directors of the French biotechnology company Blink Biomedical, which is dedicated to the development of novel antibodies in the field of immune checkpoint targets in cancer. Frédéric was also Director of the Pasteur Institute’s Tech Transfer office, where he was in charge of the licensing portfolio and strategic partnerships.